Plain-English translation of NCT05970302 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications — chemotherapy drugs (oxaliplatin and capecitabine), bevacizumab (a drug that stops blood vessels from feeding tumors), and tislelizumab (an immunotherapy drug that helps your immune system fight cancer) — can work better together than standard treatment alone for a specific type of advanced colorectal cancer. The idea is that by combining these three approaches, doctors can make the cancer more vulnerable to your immune system.
Many patients with this type of colorectal cancer do not respond well to standard chemotherapy alone. Researchers believe that adding an immune-boosting medication to chemotherapy might help more patients benefit from treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the three medications together every 3 weeks in cycles. Each cycle involves one intravenous (IV) infusion of the two IV drugs on day 1, followed by 2 weeks of taking a pill form of chemotherapy twice daily. After every 2 cycles, doctors will check how well the treatment is working using imaging scans. If you complete 8 cycles of the full combination, you would switch to a simpler maintenance regimen with fewer medications to continue treatment.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China